News

Researchers found the HDAC inhibitor-resistant cell line resistant to many therapies but highly sensitive to heat shock protein 90 inhibitors, another emerging cancer treatment.

The acquisition will bring together IVT's signature VacciMax® platform with Immunotope's portfolio of immunotherapeutic antigens and antigen discovery platform.

The collaborative research will seek to discover genetic signatures for cardiovascular disease and obesity-related hypertension.

Agreement highlights growing interest in novel biology platform that identifies clinical response of cancer drugs.

The research involves fibroblast growth factor-2 (FGF-2), a naturally occurring protein that has been studied extensively for its neuroprotective properties.

The pilot agreement with AstraZeneca to evaluate molecular services and products in cancer research.

The U.S. Patent office has issued Vermillion U.S. Patent No. 7,297,556 for aiding diagnosis of nephrotic syndrome.

ImmunoCellular has entered into an agreement with Molecular Discoveries covering the IMUC’s acquisition of all monoclonal antibody related technology owned by MDC.

Multi-site clinical trial to study GM-I’s LumaGEM® Molecular Breast Imaging (MBI) technology for early detection, diagnosis and treatment of breast cancer.

Beckman Coulter will acquire Dako's research flow cytometry instrumentation business, which is based in Fort Collins, Colorado.